Ltr Pharma Limited · ASX:LTP
Ltr Pharma — Investor Presentation (October 2025)
22 slides from Ltr Pharma's investor presentation, Oct 30, 2025
Slide 1: Lead nasal spray portfolio
For personal use only Lead nasal spray portfolio Investor Update | October 2025 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer ‣ Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd ‣ Forward looking statements: This presentation contains forward-looking information about the (Company or LTP) to provide general information about the Company. The information in th
Slide 3: Executive Summary
Executive Rapidly commercialising SPONTAN® and ROXUS® First-in-class rapid, on-demand nasal spray treatment Summary for Erectile Dysfunction (ED) LTR Pharma: Clinically validated platform with early prescriber adoption For personal use only Late-Stage Pharmaceutical Demonstrated rapid onset and cons
Slide 4: Investment Highlights
Investment Highlights LTR Pharma positioned in a clear gap in the market For personal use only Multiple path Compelling pivotal Blockbuster Blue chip Multiple upcoming to market pharmacokinetic market with issues partners milestones study data ‣ SPONTAN® active ‣ 5x faster absorption than ‣ Existing
Slide 5: Market Problem & Opportunity
For personal use only Market Problem & Opportunity
Slide 6: Understanding the Market Need
Understanding Physical causes Psychological Impact the Market Need ‣ Heart health ‣ Relationship problems A significant healthcare ‣ Hormone balance ‣ Mental wellbeing For personal use only challenge affecting ‣ Prostate Cancer ‣ Day to day stress relationships and ‣ Diabetes quality of life ‣ Medic
Slide 7: Prevalence In Key Markets
Prevalence In Key Markets As risk factors become more prevalent, so does ED Global ~322m men by 2025 For personal use only USA China Aus EU 60.7% ~30m ~33m ~150m of males 45y/o+ Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023 Investor Update | October 202
Slide 8: Estimated Market Size
Estimated Market Size Forecast to be US$6.0B market by 2028 For personal use only US$6000.00.B $5.94B 7.0% CAGR US$5000.00.B US$4000.00.B $3.68B $4,151.00 $3,867.38 US$ billions $3,614.38 US$3000.00.B $3,377.92 $3,156.94 $2,950.41 $2,757.39 $2,577.00 US$2000.00.B US$1000.00.B $1,557.00 $1,667.00 $1,
Slide 9: Current Treatments
Current Treatments Oral PDE5 inhibitors & SPONTAN® Nasal Spray Oral Phosphodiesterase-5 (PDE5) Issues with oral For personal use only inhibitors are first-line treatments PDE5 inhibitors Product Main Time before sexual Approval Generic Does not work Brand(s) activity for dose Date (US) availability
Slide 10: Nasal Administration
Nasal Administration Delivery mechanism can solve many of issues facing PDE5 inhibitors For personal use only Advantages vs oral administration Less active More rapid pharmaceutical onset of action ingredients required Higher rate of absorption Less drug degradation due to bypassing the digestive sy
Slide 11: Solution and ...
For personal use only Solution and
Slide 12: SPONTAN Pivotal Pharmacokinetic Study
SPONTAN® Pivotal Pharmacokinetic Study Rapid onset effect, consistent delivery and improved safety profile For personal use only ‣ SPONTAN® nasal spray achieved rapid absorption and Parameter Vardenafil faster onset of action compared to oral PDE5 inhibitors. (5mg) (10mg) oral ‣ SPONTAN® delivered s
Slide 13: SPONTAN The Science of Superior Delivery
SPONTAN® The Science of Superior Delivery Faster and More Potent For personal use only Speed Superiority Healthcare Professional Insight ‣ Tmax: 5 x faster than oral tablets Patients can respond in as little as 5 minutes, ‣ Peak concentration in as little as 9 mins ‣ Average onset: 12 mins vs 56 min
Slide 14: In-Market NOW
In-Market NOW Commercial Platform Active: Growing Prescriber Network ‣ RHC – experts in treating ED and early adopters of SPONTAN For personal use only 1. JV with Restorative ‣ Online bookings, consults, men’s health education, telehealth Health Clinic (RHC) solutions and prescribing SPONTAN on ‣ ht
Slide 15: US Commercialisation
US Commercialisation Multiple Active Routes to Market ROXUS > Early Market Entry via Personalised Medicine For personal use only ‣ ROXUS to be available via 503(a) personalised medicine pathway ‣ Market entry with 1st sales targeted for H1 CY2026 ‣ Focus on urology/men’s health prescribers and teleh
Slide 16: Growing Pipeline of Novel Nasal Spray Treatments
Growing Pipeline of Novel Nasal Spray Treatments Validated Platform Supporting Multiple Indications Indication/ Pre-clinical Proof of Phase 1 Phase 2 Phase 3 For personal use only Program Concept (PK study) (PK study) Erectile Dysfunction (ED) / TGA early access Available now / FDA 503(a) Personalis
Slide 17: Strategic Execution
For personal use only Strategic Execution Milestones, Partnerships and Regulatory Progress
Slide 18: Company History
Company History Progressed company substantially derisking the proposition For personal use only 2020 - 2021> 2022 > Acquired exclusive worldwide rights Establishment of the Validated the US FDA’s 505(b)(2) Optimised delivery and commercial to develop, manufacture and market SPONTAN® Scientific Advi
Slide 19: Global Co-Development Agreement
Global Co-Development Agreement Nasdaq listed Aptar Pharma Strategic partnership driving regulatory success and market readiness For personal use only Partnership Foundations Regulatory & Development Activities ‣ Strategic partnership supporting validated Extractables & Leachables (E&L) studies comm
Slide 20: SPONTAN - FDA Engagement
SPONTAN - FDA Engagement Validates Commercial Platform For personal use only Pre-IND Meeting Completed Strategic Advantage Regulatory Program ‣ FDA endorsement of overall development approach ‣ Regulatory clarity enhances development Check Points ‣ Alignment on streamlined clinical development plan
Slide 21: 2025-2026 Key Milestones
2025-2026 Key Milestones For personal use only Calendar Year Q1 2026 H1 2026 2026 Phase II Clinical Study enrolment 1st US Sales Published data ROXUS Development Completed Phase II completion and data read out OROFLOW development Human factor study completion Partnerships discussions Animal Toxicolo
Slide 22: Contact
For personal use only Contact investors@ltrpharma.com www.ltrpharma.com Authorised for release by the Board of Directors